Other

Kurume University

Takeda Pharmaceutical Company Limited

Suntory Limited

National Cerebral and Cardiovascular Center

Kenji Kangawa

Hasayuki Matsuo

Masayasu Kojima

Hisayuki Matsuo

Hiroshi Hosoda

Yoshiharu Minamitake

Kensaku Mizuno

Mikiya Miyazato

Kenji Mori

Kotaro Yuge

Yushiro Yamashita

Naoto Minamito

Kanae Oishi

Toyojiro Matsuishi

Munetsugu Hara

Takahiro Sato

The disclosure provides a non-human transgenic animal having at least one CREBBP gene locus into which a mutation has been introduced, wherein the mutated CREBBP gene encodes a mutant CREBBP consisting of an amino acid sequence having at least 90% identity with the amino acid sequence of SEQ ID NO: 5. The disclosure also provides a method of producing the transgenic animal comprising introducing a mutation into at least one CREBBP gene locus of a non-human animal. The disclosure further provides use of the transgenic animal as a model of Rubinstein-Taybi syndrome or advanced sleep phase syndrome.

Transgenic animal having CREBBP gene into which mutation has been introduced

A method of treating Rett Syndrome (RTT) comprising administering ghrelin to a subject in need thereof.

Method of treating Rett Syndrome (RTT) with ghrelin

The present invention provides a peptide-type compound which induces secretion of growth hormone and which has the activity of increasing the intracellular calcium ion concentration, wherein at least one amino acid is replaced by a modified amino acid and/or a non-amino acid compound, or a pharmaceutically acceptable salt thereof.

Modified ghrelin peptides

Modified gherlin peptides

The present invention provides a variety of useful polypeptides. In particular, a polypeptide comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, SEQ ID NO: 2 or SEQ ID NO: 3, its amide, or a salt thereof can be used as an agent for preventing/treating hypotension; an agent for preventing/treating obesity, hyperphagia, etc.; an agent for preventing/treating lethargy, time-zone change syndrome (jet lag), etc.; an agent for preventing/treating sterility, etc. A compound or its salt that promotes the activity of a polypeptide comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by any of SEQ ID NOS: 7 to 12 and 37 to 42, its partial peptide, or a salt thereof is useful as an agent for preventing/treating, e.g., menopausal symptoms or hyperthyroidism. A compound or its salt that inhibits the activity of said polypeptide is useful as an agent for preventing/treating, e.g., sterility or hypothyroidism.

Polypeptide and the use thereof

Modified ghrelin polypeptides

A cDNA coding for a rat derived CNP (rCNP: C-type natriuretic pepteide), and a rat derived CNP precursor protein and derivatives thereof are disclosed. The rat derived CNP precursor is represented by the following amino acid sequence.

Rat CNP complementary DNA and precursor protein

The invention relates to a C-terminal .alpha.-amidating enzyme of porcine origin having the following properties: (1) the action is on a peptide or protein represented by the formula:

C-terminal .alpha.-amidating enzyme and process for production thereof

Growing community of inventors

Toyonaka, Japan

Masayasu Kojima